GIS:FRA
Gilead Sciences, Inc
133,44 €
arrow_upward
+1,03%(+1,36) 1 D.
09-29, 08:01:09 GMT+2 · EUR
search
Visi simboliai
1 D.
5 D.
1 MĖN.
6 MĖN.
NUO METŲ PRADŽIOS IKI DABAR
1 M.
5 M.
MAKS.
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „GIS“ įžvalgos...
Atidaryti
133,44 €
Aukšta
133,44 €
Žema
133,44 €
Rinkos kapitalizacija
186,02 mlrd.
Vid. kiekis
454,00
Apimtis
0,00
52 sav. aukšta
134,58 €
52 sav. žema
93,70 €
Darbuotojų skaičius
17 tūkst.
Atidaryti
133,44 €
Aukšta
133,44 €
Žema
133,44 €
Rinkos kapitalizacija
186,02 mlrd.
Vid. kiekis
454,00
Apimtis
0,00
52 sav. aukšta
134,58 €
52 sav. žema
93,70 €
Darbuotojų skaičius
17 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Yahoo Finance
·
prieš 19 valandų
Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?
AD HOC NEWS
·
prieš 19 valandų
Gilead Sciences stock last trades at USD 152.43 on September 28, 2026
Yahoo Finance
·
prieš 19 valandų
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?
Insider Monkey
·
prieš 20 valandų
Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?
Profilis
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Apie „Gilead Sciences, Inc“
Generalinis direktoriusDaniel O'Day
Darbuotojai17 tūkst.
Įkurta1987-06-22
Pagrindinė būstinėFoster Sitis, Kalifornija, Jungtinės Valstijos
Sektorius-
Svetainėgilead.com